EUVIMEDEUVIMED entdecken
Übersichtsarbeit

First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation

J Nicholas Bodor, Vineela Kasireddy, Hossein Borghaei

Journal of Oncology Practice · 2018-09 · 14 (9) · 529-535

DOI: 10.1200/jop.18.00250 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Oncology Practice, 2018-09. Verfasst von J Nicholas Bodor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fox Chase Cancer Center, Philadelphia, PA. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the leading cause of cancer-related death worldwide. The majority of these cancers are non–small-cell lung cancer, of which adenocarcinoma is the most common histologic subtype. Most patients are diagnosed at advanced stages when systemic treatment is needed. Whereas prognosis has improved for patients with targetable driver mutations, the majority of patients do not possess tumors with such molecular mutations. Platinum-based chemotherapy has traditionally been the mainstay of treatment, although in recent years immunotherapy has emerged as a treatment option and can result in robust and durable treatment responses in a subset of patients. Recent clinical trials on novel immunotherapy combinations and immunochemotherapy combinations may broaden the number of patients that may benefit from checkpoint inhibitors and elicit responses in those who otherwise may not have experienced a response to monotherapy with an immunotherapy drug. This review will outline the currently available therapies for the first-line treatment of metastatic adenocarcinoma that do not possess a driver mutation and provide a recommended approach and algorithm by which to select the best first-line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorHumansImmunotherapyLung NeoplasmsMutationPlatinum Compounds

Substanzen

Antineoplastic AgentsBiomarkers, TumorPlatinum CompoundsBevacizumab

Autor:innen und Institutionen

  • Fox Chase Cancer Center, Philadelphia, PA.

Zitieren

APA

Bodor, J. N., Kasireddy, V., & Borghaei, H. (2018). First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. Journal of Oncology Practice, 14(9), 529-535. https://doi.org/10.1200/jop.18.00250

Vancouver

Bodor JN, Kasireddy V, Borghaei H. First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. Journal of Oncology Practice. 2018;14(9):529-535. doi:10.1200/jop.18.00250

BibTeX
@article{Bodor2018,
  author = {Bodor, J Nicholas and Kasireddy, Vineela and Borghaei, Hossein},
  title = {First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation},
  journal = {Journal of Oncology Practice},
  year = {2018},
  volume = {14},
  number = {9},
  pages = {529--535},
  doi = {10.1200/jop.18.00250}
}
Kostenlos starten →